Fennec Pharmaceuticals (TSE:FRX) has released an update.
Fennec Pharmaceuticals has entered into an exclusive agreement with Norgine to commercialize PEDMARQSI, a therapy for preventing hearing loss in pediatric cancer patients undergoing cisplatin chemotherapy, across Europe, Australia, and New Zealand. The deal includes an upfront payment of €40 million to Fennec, with potential for €210 million more based on commercial and regulatory milestones, plus royalties. This partnership aims to address a significant unmet medical need and marks a critical step in making PEDMARQSI a standard treatment in these regions.
For further insights into TSE:FRX stock, check out TipRanks’ Stock Analysis page.
